Tetra Bio-Pharma Inc., an innovator in cannabinoid-derived drug discovery and development, has engaged Alpha Bronze LLC., by its principal, Mr. Pascal Nigen, an investor relations, management consulting and financial communications firm to implement and execute a comprehensive investor relations and communications program.
“I am very pleased and excited to have engaged Alpha Bronze as our new IR firm. They have demonstrated in a recent mandate provided to them that they have an excellent investors network and know-how of financial communications for the Health Care sector in the United States. In addition, their level of engagement in supporting their clients will be key for Tetra Bio-Pharma moving forward with its business execution,” stated Sylvain Chretien, the newly appointed President of Tetra Bio-Pharma. “I would like to thank EnergiPR and LifeSci for their support and contributions to Tetra.”
The agreement for the engagement of Alpha Bronze commenced on March 1, 2020 for a term of 12 months. Alpha Bronze will be paid fees of US$10,000 per month for its services, and received 200,000 stock options, for a period of 3 years with 50,000 options vesting immediately, 50,000 options vesting on May 18, 2020, and the remaining 100,000 options vesting over conditional milestones. The options have an exercise price of $0.42.
Tetra has provided notices of termination to LifeSci Advisors and LifeSci Public Relations as well as EnergiPR as part of the transition in investor relations and public relations services to Alpha Bronze. These terminations account for a net saving for approximately US$38,000 per month.
Please visit www.alphabronzellc.com for more information about Alpha Bronze.